GATA3 positivity is associated with poor prognosis in patients with oesophageal squamous cell carcinoma

J Clin Pathol. 2023 Jul;76(7):474-479. doi: 10.1136/jclinpath-2021-208035. Epub 2022 Jan 17.

Abstract

Aims: GATA-binding protein 3 (GATA3) is a zinc finger transcription factor with diverse biological functions and is an excellent diagnostic marker for breast and urothelial carcinoma. We aimed to study GATA3 expression in oesophageal squamous cell carcinoma (SCC) and its significance with respect to histological features, clinical parameters and overall survival.

Methods: We characterised GATA3 immunohistochemistry in 40 patients with oesophageal SCC. Electronic medical records were reviewed for clinical and follow-up information, as well as patient survival.

Results: Eleven (28%) oesophageal SCC were positive for GATA3. The predominant stain patterns were patchy, with either mild or moderate intensities. Patients with GATA3-positive tumours showed significantly shorter overall survival than those with GATA3-negative tumours (p=0.023, Kaplan-Meier survival analysis with log-rank test). In the multivariate Cox proportional hazards regression model, GATA3 positivity was an independent adverse prognostic factor for overall survival (p=0.019, HR 5.671). Surgery, definitive chemotherapy and/or radiotherapy, and initial clinical stage were confirmed as independent prognostic factors.

Conclusion: To the best of our knowledge, this is the first study to investigate the incidence of GATA3 positivity in oesophageal SCC and showed GATA3 positivity is associated with poor prognosis in oesophageal SCC.

Keywords: esophagus; immunohistochemistry; pathology; surgical.

MeSH terms

  • Biomarkers, Tumor / metabolism
  • Carcinoma, Transitional Cell*
  • Esophageal Neoplasms* / pathology
  • Esophageal Squamous Cell Carcinoma*
  • GATA3 Transcription Factor / metabolism
  • Humans
  • Prognosis
  • Urinary Bladder Neoplasms*

Substances

  • GATA3 Transcription Factor
  • Biomarkers, Tumor
  • GATA3 protein, human